Mitesco, Inc. received an additional $125,000 in funding on February 23, 2026, from C/M Capital Master Fund, LP. This funding is part of a Senior Secured 10% Original Issue Discount Convertible Promissory Note (2025 Bridge Note), obligating the company to repay $137,500 for this tranche. The note has an 18-month term and bears no interest unless an Event of Default occurs, at which point interest accrues at 10% per annum. The note is convertible into common stock at $0.15 per share, subject to certain adjustments, including an 'Alternative Conversion Price' of 70% of the lowest VWAP over 20 trading days if an Event of Default or Equity Condition failure occurs. The company has received a total of $625,000 in funding under these notes over the last 12 months. Obligations under the 2025 Bridge Note are guaranteed by the company's subsidiaries (Centcore LLC, Vero Technology Ventures, LLC, and The Good Clinic, LLC) and are secured by a first priority senior security interest in all the company's assets and a pledge of the equity interests of its subsidiaries. The company may prepay the note at 110% of the then outstanding principal amount. Investors have the right to participate in future equity financings up to 25% of the offering at a 10% discount to the offering price. A 'Most Favored Nation' clause allows investors to exchange notes for securities of a subsequent financing on the same terms if more favorable, based on 110% of the note's principal plus accrued interest.